Skip to content
Tenfell
Closed tender
Published 18 Jan 2018

NHS Pharmaceuticals 2017_2

NHS England · London

Key facts

Estimated value
£45,850,500
Closing date
26 Jan 2018
Contract starts
31 Jul 2018
Contract ends
31 Jan 2020
Procedure
Open procedure
Buyer type
Central government

Description

NHS Pharmaceuticals 2017_2. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months. Potential periods of call-offs under the framework agreement: CESW regions: 1.8.2018 to 28.2.2019 (7 months). NWLN regions: 1.8.2018 to 31.7.2019 (12 months). LSNE regions: 1.8.2018 to 31.1.2020 (18 months). Products on the framework include (but are not necessarily limited to): Abacavir, Abiraterone, Anidulafungin, Atovaquone, Bosentan, Ciclesonide, Drospirenone/Ethinylestradiol, Enfurvitide, Ethinylestradiol/Norelgestromin, Exenatide, Ezetimibe, Iloprost, Ivabradine, Mycophenolic acid, Nitisinone, Olopatadine, Oseltamivir, Parecoxib, Pegfilgrastim, Pegvisomant, Pregabalin, Tadalafil, Tenofovir, Tigecycline, Valproic acid, Velaglucerase. Details of regions, presentation sizes and volumes are within the tender document set.

Additional information: The procurement exercise is being conducted on the NHS England eTendering portal at www.nhsengland.bravosolution.co.uk the project code is tender_1479 and the ITT code is itt_422. This is where the ITO documents are available.

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.